Diversified Trust Co decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,200 shares of the biopharmaceutical company’s stock after selling 805 shares during the period. Diversified Trust Co’s holdings in Regeneron Pharmaceuticals were worth $2,554,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Korea Investment CORP boosted its position in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $140,000. Alpha Windward LLC boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Wendell David Associates Inc. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $204,000. Finally, Welch & Forbes LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $211,000. 66.79% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 468.76 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The company has a 50-day moving average price of $499.60 and a 200-day moving average price of $421.63. The company has a market capitalization of $49.49 billion, a price-to-earnings ratio of 56.74 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $13.63 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/06/diversified-trust-co-lowers-position-in-regeneron-pharmaceuticals-inc-regn-updated-updated.html.
A number of research analysts have commented on the company. UBS AG set a $489.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. BMO Capital Markets set a $491.00 price objective on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday. Citigroup Inc. boosted their price objective on Regeneron Pharmaceuticals to $575.00 and gave the stock a “buy” rating in a research note on Friday. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday. Finally, Canaccord Genuity set a $522.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $477.91.
In other news, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the transaction, the executive vice president now owns 43,950 shares in the company, valued at $23,405,572.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanofi purchased 136,050 shares of the stock in a transaction that occurred on Friday, June 2nd. The stock was bought at an average cost of $478.17 per share, with a total value of $65,055,028.50. The disclosure for this purchase can be found here. Insiders sold 59,396 shares of company stock valued at $28,484,734 in the last quarter. 10.40% of the stock is currently owned by corporate insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
